Ampersand Capital Partners completes Growth Equity Investment in Transplantation Diagnostic firm GenDx
Genome Diagnostics B.V. (“GenDx”) announced today that Ampersand Capital Partners has completed a minority, growth equity investment in the company. Wietse
Mulder, PhD., remains the majority shareholder and CEO of GenDx. The partnership between Ampersand and GenDx aims to foster sustainable growth, both organically and through M&A activities in the molecular diagnostic products and services market.
GenDx is a leading provider of molecular diagnostic kits and analysis software for transplantation and companion diagnostics. Dr. Mulder commented: “GenDx has been successfully organized as a fully independent organization for almost fifteen years. We are delighted to partner with Ampersand and together continue to live by our vision of ‘meaningful entrepreneurship’ by offering the best products, education, and services to the transplantation community worldwide.”
David Parker, a General Partner at Ampersand, added: “Given Ampersand’s prior experience in the transplantation and NGS markets, we were highly impressed by the differentiated product and service offering of GenDx. We are excited to partner with Dr. Mulder and the GenDx team to build on the
company’s long history of profitable growth.”
In connection with this transaction, David Parker has joined the GenDx Board of directors along with Ampersand Operating Partner Mike Evans, PhD. They join three founders on the GenDx Board: Dr. Mulder, Raoul Linschoten, LLM (Chairman), and Oscar Schoots, PhD. The board will be supported by non-director advisors Larry McCarthy, PhD and Frank Witney, PhD., both seasoned entrepreneurs and executives who serve as Operating Partners at Ampersand.